Head and Neck Cancer, Lung Cancer
Conditions
Keywords
head and neck cancer, lung cancer, tobacco use disorder, alcoholism
Brief summary
This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer
Detailed description
Continuing the chronic intoxication by either tobacco or alcohol after the initial diagnosis of a first lung or head and neck cancer significantly improves the risk of experiencing a second cancer, and largely affects the long term survival. Addiction intervention programs should be personalized according to the patient's profile, with the aim to develop more sustained intervention and monitoring in patients identified at higher risk of not spontaneously stopping harmful substance use. As of today, the trajectories of smoking and drinking habits and the risk factors for persisting smoking or drinking habits have been insufficiently explored among patients with a first lung or head and neck cancer. The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer. The secondary objectives of the study are: * to depict the rate of alcohol users 12 months after the initial diagnosis of a H&N cancer * to depict the rate of tobacco smokers at cancer diagnosis * to depict the rate of alcohol users at cancer diagnosis * to determine the social, motivational, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC. * to determine the social, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first H&N cancer
Interventions
BEHAVIORALphysician assessment
* Socio-economic conditions and general features: educational level, professional status... * Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level... * in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test... * Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months... * Assessment of current use of cannabis using the Cannabis Abuse Screening Test * Psychiatric assessment using the MINI 5.0
Sponsors
Centre Oscar Lambret
Centre Régional de Référence en Cancérologie
National Cancer Institute, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* first head and neck or lung cancer * first support * age ≥ 18 * patient covered by health insurance * signed informed consent
Exclusion criteria
* prior lung or head and neck cancer * History of another cancer \<5 years, not evolutive and untreated at baseline (carcinoma of the cervix, or basal cell carcinoma of the skin properly treated are allowed). The presence of a second discovery tumor location at the same time as the lung or head and neck cancer, is not a criteria for non-inclusion * mesothelioma and oesophageal cancer * unable to undergo trail medical follow up (geographical, social and psychological reasons) * pregnant or nursing women * patient under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tobacco consumption | at 12 months | reported tobacco smoking |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| tobacco smoking | at baseline, 3 and 6 months | frequency tobacco consumption |
| alcohol drinking | at baseline, 3, 6 and 12 months | frequency of alcohol consumption |
| progression free survival | at 12 months | median time between date of inclusion and date of first progression |
| overall survival | at 12 months | median time between date of inclusion and date of death |
| sociodemographic, cancer-related, tobacco-related, alcohol-related, and psychiatric characteristics | at baseline | — |
Countries
France
Contacts
STUDY_DIRECTORCorinne VANNIMENUS, MD
Centre Hospitalier Régional et Universitaire LILLE
Outcome results
None listed